This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Safety Profile | Reducing Risk of DVT/PE Recurrence | Pradaxa® (dabigatran etexilate) Skip to main content

*Patients in the treatment studies who rolled over into the RE-MEDY study had a combined treatment duration of up to >3 years, with mean exposure of 473 days.
Patients with at least one major bleeding event.
Patients in the treatment studies who rolled over into the RE-SONATE® study had a combined treatment duration of up to 9 months, with mean exposure of 165 days.

  • References:
  • 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.